Multiple sclerosis. Multiple sclerosis
Conditions
Interventions
Intervention 1: Intervention group: Participants will receive two 2 Dineh garlic tablets daily for 10 weeks (one after lunch and one after dinner). Each tablet contains 400 mg dried garlic powder stan
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Adults aged 18–55 years Confirmed diagnosis of RRMS (2017 McDonald criteria) EDSS score = 5.5 Ability and willingness to provide informed consent Ability to adhere to daily supplementation
Exclusion criteria
Exclusion criteria: Known allergy to garlic History of severe gastrointestinal disorders Uncontrolled psychiatric disorders Active malignancy Presence of other autoimmune diseases Use of medications affecting coagulation or platelet function change in MS medications or corticosteroid use within the past 3 months Active infection or systemic illness at the time of enrollment Pregnancy or breastfeeding Inability or unwillingness to cooperate with study procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Antioxidant Capacity (TAC). Timepoint: At the beginning of the study and 10 weeks after the intervention. Method of measurement: Laboratory kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Interleukin 6 (IL-6). Timepoint: At the beginning of the study and 10 weeks after the intervention. Method of measurement: Laboratory kit.;C-reactive protein (CRP). Timepoint: At the beginning of the study and 10 weeks after the intervention. Method of measurement: immunoturbidimetric assay using an automated analyzer.;Erythrocyte Sedimentation Rate (ESR). Timepoint: At the beginning of the study and 10 weeks after the intervention. Method of measurement: Westergren method.;Malondialdehyde (MDA). Timepoint: At the beginning of the study and 10 weeks after the intervention. Method of measurement: Laboratory kit.;Glutathione Peroxidase (GPx). Timepoint: At the beginning of the study and 10 weeks after the intervention. Method of measurement: Laboratory kit.;Superoxide Dismutase (SOD). Timepoint: At the beginning of the study and 10 weeks after the intervention. Method of measurement: Laboratory kit.;Timed 25-Foot Walk (T25-FW). Timepoint: At the beginning of the study and 10 weeks after the intervention. Method of measurement: Assessed by a neurologist.;Expanded Disability Status Scale (EDSS). Timepoint: At the beginning of the study and 10 weeks after the intervention. Method of measurement: Assessed by a neurologist (McDonald criteria).;Fasting Blood Sugar. Timepoint: At the beginning of the study and 10 weeks after the intervention. Method of measurement: Enzymatic.;Lipids profile (Total-C, TG, HDL-C, LDL-C). Timepoint: At the beginning of the study and 10 weeks after the intervention. Method of measurement: Enzymatic colorimetric methods for TC, TG, and HDL-C. LDL-C will be calculated using the Friedewald's formula: LDL-C = TC - HDL-C - (TG/5).;Blood pressure. Timepoint: At the beginning of the study and 10 weeks after the intervention. Method of measurement: BEURER-BM44 digital blood pressure monitor.;Pain intensity. Timepoint: At the beginning of the study and 10 weeks after the intervention. Method of measurement: Visual Analog Scale (VAS).;Fatigue severity. Ti | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Keshavarz
Ahvaz University of Medical Sciences
Outcome results
None listed